 |
|
|
 |
Staph Bacteria Are Prolific Gene Swappers, Researchers Show
When some disease-causing bacteria encounter a new obstacle, they simply swap DNA with their relatives to acquire the genes needed to overcome it. And they do so quite readily, according to scientists from the National Institute of Allergy and Infectious Diseases (NIAID). The research reveals how Staphylococcus aureus, the common "staph" bacterium responsible for several human infections, has repeatedly adapted to novel environments and conditions. The research offers new approaches to antibiotic and vaccine design, and answers long-standing questions about the origins of both diseases: toxic shock syndrome (TSS) and antibiotic-resistant infections. more
|
|
Potency of HIV Agents Lamivudine And Emtricitabine Differs
New research comparing the in vitro antiviral potency of Epivir(R) (lamivudine, GlaxoSmithKline) or 3TC and emtricitabine or FTC contradicts earlier study results and found no significant difference between the two drugs when potency is compared in a broader range of in vitro cultured cell types. The new study was presented here today at the International AIDS Society (IAS) conference. more
|
|
|
|
Nevirapine Treatment Combination As Effective As Protease-Inhibitor-Based Regimen In Suppressing HIV
Final one-year results of the international COMBINE study show that an anti-HIV treatment regimen of Viramune(R) (nevirapine) plus Combivir(TM) (3TC/ZDV)* demonstrated comparable efficacy, when compared to a regimen of the protease inhibitor nelfinavir* plus Combivir, in reducing HIV below detectable limits. The findings were presented at the first International AIDS Society Conference on HIV Pathogenesis and Treatment. more
|
|
Tipranavir Shown To Suppress HIV In Patients Where Multiple Protease Inhibitor-Based Regimens Have Failed
Findings presented today demonstrate the antiretroviral potency and durability of tipranavir in protease inhibitor-experienced patients. Tipranavir is the first non-peptidic protease inhibitor (NPPI) in development for the treatment of HIV-1 infection. The data was released at the First International AIDS Society Conference on HIV Pathogenesis and Treatment. more
|
|
Oncology Patients At Increased Risk Of Fatal Thromboembolism
Cancer patients are at high risk of potentially fatal blood clots that form in the large veins in the leg (venous thromboembolism) that, if unrecognized or untreated, can lead to a potentially fatal pulmonary (lung) embolism. In fact, as many as 1 in 7 hospitalized cancer patients die of a fatal thromboembolic event rather than their cancer. more
|
|
|
